The company stated that its multiple sclerosis drug candidate, part of a class of compounds that has been linked to cases of liver damage, reduced brain lesions in a mid-stage trial and that no new safety concerns emerged.
https://www.pharmalive.com/wp-content/uploads/2021/10/Roche-launches-genomic-profiling-kit-to-ease-cancer-research-Reuters-10-25-21.jpeg171295Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-05-17 02:49:512023-05-17 09:56:11Roche says new MS drug shown to reduce brain lesions
